Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Oncogenic ras alleles are among the most common mutations found in patients with acute myeloid leukemia (AML). Previously, the role of oncogenic ras in cancer was assessed in model systems overexpressing oncogenic ras from heterologous promoters. However, there is increasing evidence that subtle differences in gene dosage and regulation of gene expression from endogenous promoters play critical roles in cancer pathogenesis. We characterized the role of oncogenic K-ras expressed from its endogenous promoter in the hematopoietic system using a conditional allele and IFN-inducible, Cre-mediated recombination. Mice developed a completely penetrant myeloproliferative syndrome characterized by leukocytosis with normal maturation of myeloid lineage cells; myeloid hyperplasia in bone marrow; and extramedullary hematopoiesis in the spleen and liver. Flow cytometry confirmed the myeloproliferative phenotype. Genotypic and Western blot analysis demonstrated Cre-mediated excision and expression, respectively, of the oncogenic K-ras allele. Bone marrow cells formed growth factor-independent colonies in methylcellulose cultures, but the myeloproliferative disease was not transplantable into secondary recipients. Thus, oncogenic K-ras induces a myeloproliferative disorder but not AML, indicating that additional mutations are required for AML development. This model system will be useful for assessing the contribution of cooperating mutations in AML and testing ras inhibitors in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Expression of the most common KRAS mutation (G12D) in mouse hematopoietic cells causes a fatal myeloproliferative neoplasm (MPN).6,7”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617 · cited 3×
“Myeloid progenitors were distinguished as Lin–Sca-1–c-Kit+CD34+FcγRII/IIIlo common myeloid progenitors (CMPs), Lin–Sca-1–cKit+CD34+FcγRII/IIIhi granulocyte-monocyte progenitors (GMPs), and Lin–Sca-1–c-Kit+CD34–FcγII/IIIlo megakaryocyte-erythrocyte progenitors (MEPs) (43).”
BackgroundSelf-citationAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 4×
“floxed LSL–K-ras G12D allele (38) containing a transcriptional ter-”
BackgroundResultInfluentialSelf-citationDaley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756 · cited 4×
“The Journal of Clinical Investigation | February 2004 | Volume 113 | Number 4 537 Growth factor–independent colony-forming activity of bone marrow cells has also been described in TEL-JAK2 and BCR/ABL murine bone marrow transplant models (51, 52).”
InfluentialInducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,641 · cited 4×
“In studies of Mx1-Cre–mediated recombination of a floxed DNA polymerase β gene, pI-pC treatment yielded high recombination efficiencies in hematopoietic tissues (liver, 100%; spleen, 94%; and thymus, 40%) and lower levels in nonhematopoietic tissues such as heart, kidney, lung, and duodenum (37).”
BackgroundMethodInfluentialThe roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558 · cited 1×
“Examples of tyrosine kinase gain-of-function mutations in AML include FLT3 activation loop point mutations, FLT3 juxtamembrane region internal tandem duplications (ITDs) (14), C-KIT point mutations (15), and the tyrosine kinase fusion products of chromosomal translocations such as TEL/ TRKC associated with t(12;15) (1…”
BackgroundSelf-citationSomatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179 · cited 2×
“Papillomas and thymic lymphomas have been previously observed in 30% of adenovirus-Cre–treated oncogenic K-ras mice (40).”
BackgroundMethodSelf-citationSong, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., et al. (1999) · Nature Genetics · doi:10.1038/13793 · Cited by 1,100 · cited 2×
“KM – 8–83 (35) 34–53 (41) 156–885 (583) 70–1,271 (540) 704–2,777 (1491) MPD n = 6 n = 6 n = 6 n = 8 n = 8”
BackgroundSelf-citationRodriguez-Viciana, P., Warne, P. H., Khwaja, A., Marte, B. M., Pappin, D., Das, P., Waterfield, M. D., Ridley, A., & Downward, J. (1997) · Cell · doi:10.1016/s0092-8674(00)80226-3 · Cited by 1,061
Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., & Leder, P. (1987) · Cell · doi:10.1016/0092-8674(87)90449-1 · Cited by 792 · cited 1×
“Transgenic mice expressing viral H-ras from the MMTV promoter/enhancer developed B cell lymphoblastic lymphomas at low frequency (34).”
Background
Cited by
Items 201–272 of 272
Mouse Models of Human Blood Cancers: Basic Research and Pre-clinical Applications
Li, S. (2008) · Springer eBooks · doi:10.1007/978-0-387-69132-9 · Cited by 6
Gong, J., Wang, Z., Polejaeva, I. A., Salgia, R., Kao, C.-M., Chen, C.-T., Chen, G., & Chen, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090059 · Cited by 5
“Based on the genome data [24,25], goat K-ras promoter region is very rich in G and C, lacks TATA and CCAAT boxes, and contains sequence similarities with other house-keeping genes, such as dihydrofolate reductase (DHFR) and epidermal growth factor (EGF) receptor genes.”
BackgroundAdvances in the Development of Animal Models of Myeloid Leukemias
Guryanova, O. A., & Levine, R. L. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.03.027 · Cited by 5
Mouse Model for ‐Induced Leukemogenesis
Parikh, C., & Ren, R. (2008) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)00402-8 · Cited by 5
Karra, L., Finger, A., Shechtman, L. A., Krush, M., Huang, M., Prinz, M., Tenvooren, I., Bahl, K., Hysienaj, L., García-González, P. A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014411 · Cited by 4
“The KRas G12D / Mx1CRE model 18,19 allows for induction of the G12D mutation in KRas, expressed of the endogenous KRas locus.”
Targeted Approaches to Drug Development
Stegmaier, K., & Sellers, W. R. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3431-5.00004-2 · Cited by 4
Epigenetic response of imprinted domains during carcinogenesis
Bretz, C. L., Langohr, I. M., & Kim, J. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0393-8 · Cited by 4
“The enzymes mainly responsible for de novo methylation are Dnmt3a and Dnmt3b, while Dnmt1 preferentially targets hemimethylated DNA to maintain DNA methylation patterns [18,19].”
BackgroundResultGenetically modified mouse models in cancer studies
Santos, J., Fernández‐Navarro, P., Villa‐Morales, M., González-Sánchez, L., & Fernández‐Piqueras, J. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0292-8 · Cited by 6
“Kras Conditional lox-STOP-lox-Kras2, expressing Non-small-cell lung adenocarcinoma (when intranasal [16, 77 ] activating mutant oncogene after Cre-mediated administration of Adenovirus-Cre); pancreatic adenocarcinoma excision of a STOP cassette (after crossing with Pdx-1-Cre transgenic mice); myeloproliferative diseas…”
MethodNoonan syndrome: lessons learned from genetically modified mouse models
Schuhmacher, A. J., Hernández-Porras, I., García-Medina, R., & Guerra, C. E. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1361821 · Cited by 4
“Interestingly, K-Ras mice develop MPD [56], as well as K-Ras mice [59,86].”
BackgroundWandler, A. M., & Shannon, K. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031526 · Cited by 4
“To examine the effects of oncogenic Kras expression in the hematopoietic compartment, two groups intercrossed LSL-KrasG12D and Mx1-Cre mice (Braun et al. 2004; Chan et al. 2004).”
BackgroundLack of KRAS Gene Mutations in Chronic Myeloid Leukemia in Iran
Kooshyar, M. M., Ayatollahi, H., Keramati, M. R., Sadeghian, M. H., Miri, M., & Sheikhi, M. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.11.6653 · Cited by 3
“Activated RAS stimulates RAF and mitogen-activated protein (MAP) kinase cascade to transmit growth signals to the nucleus (Chan et al., 2004; Stricker et al., 2010).”
BackgroundInfluentialChronic myeloproliferative disorders
Niemeyer, C. M., & Locatelli, F. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511977633.020 · Cited by 4
Murine Models of Hematopoietic Disease: Pathologic Analysis and Characterization
Lee, B. H., & Kutok, J. L. (2008) · Springer eBooks · doi:10.1007/978-0-387-69132-9_3 · Cited by 3
Self-citationOncogenic Kras and Notch-1 cooperate in T-cell acute lymphoblastic leukemia/lymphoma
Mansour, M. R. (2009) · Expert Review of Hematology · doi:10.1586/ehm.09.3 · Cited by 3
Koh, C. P., Bahirvani, A. G., Wang, C. Q., Yokomizo, T., Ng, C. E. L., Du, L., Tergaonkar, V., Voon, D. C., Kitamura, H., Hosoi, H., et al. (2022) · Gene · doi:10.1016/j.gene.2022.147049 · Cited by 3
Jiang, Y., Jenjob, R., Ryu, D., Shen, Z., & Yang, S. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.06.024 · Cited by 2
“However, KRAS mutations result in the hyperactivation of the KRAS protein, keeping it in the “on” state, and leading to uncontrolled cell growth 10 .”
Aspectos biológicos e atividade tumorigênica da família proto-oncogênica Ras
Boquett, J. A., & Ferreira, R. J. (2010) · Semina Ciências Biológicas e da Saúde · doi:10.5433/1679-0367.2010v31n2p201 · Cited by 2
Progression and perspectives in disease modeling for Juvenile myelomonocytic leukemia
Fu, S., Guo, Y., Peng, Z., Zhang, D., Chang, Z., Xiao, Y., Zhang, Q., Yu, L., Chen, C., Chen, Y., et al. (2024) · Medical Oncology · doi:10.1007/s12032-024-02549-5 · Cited by 2
Jang, G., Park, R., Esteva, E., Hsu, P.-F., Feng, J., Upadhaya, S., Sawai, C. M., Aifantis, I., Fooksman, D., & Reizis, B. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20240587 · Cited by 3
NF1 Mutations in Hematologic Cancers
Chang, T. Y., & Shannon, K. (2012) · Springer eBooks · doi:10.1007/978-3-642-32864-0_30 · Cited by 2
“UsingMx1-Cre to activate endogenous oncogenic Kras expression causes a JMML-likeMPN in mice, which progresses rapidly, leading to death by 4 months of age (Braun et al. 2004; Chan et al. 2004).”
BackgroundBiochemical and Biological Functions of Isoprenylcysteine Carboxyl Methyltransferase
(2011) · The Enzymes · doi:10.1016/b978-0-12-415922-8.00004-5 · Cited by 4
“Mx1-Cre;LSL-KRAS mice that were wild type for Icmt [82,83] were found to develop a fatal myeloproliferative disorder with 100% penetrance after injection with pI–pC.”
BackgroundKRasG12D-evoked leukemogenesis does not require β-catenin
Ng, C. E. L., Sinha, A., Krivtsov, A. V., Dias, S., Chang, J. C., Armstrong, S. A., & Kalaitzidis, D. (2013) · Leukemia · doi:10.1038/leu.2013.328 · Cited by 2
Targeting RAS Signaling Pathways in Juvenile Myelomonocytic Leukemia (JMML)
Lauchle, J., & Braun, B. S. (2010) · Springer eBooks · doi:10.1007/978-0-387-69062-9_7 · Cited by 2
“Similar conditional alleles have also been used to model effects of dominant oncogenes such as Kras and Ptpn11 (Braun et al. 2004; Chan et al. 2004, 2009 ).”
Mouse Models in Cancer Research
Lee, S., & Schmitt, C. A. (2006) · Wiley eBooks · doi:10.1002/9783527619665.ch26 · Cited by 2
Ahmad, E., Gawish, H. H., Alazizi, N. M., & Elhefni, A. M. (2009) · PubMed · Cited by 1
The Role and Impact of Non-driver Gene Mutations in Myelofibrosis
Boldrini, V., Guglielmelli, P., & Vannucchi, A. M. (2026) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-026-00773-6 · Cited by 1
“The induction of het - erozygous KRAS G12D/+ expression in the hematopoietic system alone leads to a rapid and highly penetrant myeloproliferative phenotype [77], while heterozygous NRAS G12D produces a milder phenotype [78].”
Molecular Markers for Risk Stratification in Adult Acute Myeloid Leukemia with Normal Cytogenetics
Fuchs, O. (2011) · InTech eBooks · doi:10.5772/19844 · Cited by 2
“Ras-signaling cascade contributes to the molecular pathogenesis of myeloproliferative disorders (Chan et al., 2004).”
BackgroundInfluentialCurrent Insights in the Cellular and Molecular Biology of Chronic Myelomonocytic Leukemia
Itzykson, R., Droin, N. M., & Solary, É. (2012) · International Journal of Hematologic Oncology · doi:10.2217/ijh.12.19 · Cited by 1
Akın, D. F., Öner, D. A., Mumcuoğlu, M., Ezer, Ü., Bahçe, M., Kürekçi, E., & Akar, N. (2015) · Egyptian Journal of Medical Human Genetics · doi:10.1016/j.ejmhg.2015.09.002 · Cited by 1
Weir, M. C. (2016) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Molecular pathogenesis of Helicobacter hepaticus induced liver disease
Boutin, S. R. (2005) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 1
Bullinger, L., Döhner, H., & Pollack, J. R. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-576-3_8
“However, constitutively activated signaling molecules, such as FLT3 or RAS family members, can induce a myeloproliferative phenotype (Kelly et al., 2002 ; Chan et al., 2004) .”
Backgrounddos Santos, E. O. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.46.2013.tde-15012014-143156 · Cited by 2
Genetic Modeling of Human Blood Cancers in Mice
Hu, Y., & Li, S. (2008) · Springer eBooks · doi:10.1007/978-0-387-69132-9_2
“topoietic system, K-ras induces a myeloproliferative disease, but it is not sufficient to induce AML (Braun et al., 2004; Chan et al., 2004).”
BackgroundHematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia
Niemeyer, C. M., & Locatelli, F. (2015) · Wiley eBooks · doi:10.1002/9781118416426.ch49
Defining RCE1 and ICMT as Therapeutic Targets in K-RAS-induced Cancer
Wahlstrom, A. M. (2009) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Genomic and Epigenomic Studies of Acute Myeloid Leukemia with CEBPA Abnormalities
Wouters, B. J. (2009) · EUR Research Repository (Erasmus University Rotterdam)
Studies on Genetic Aberrations in Acute Myeloid Leukemia
Abbas, S. (2011) · EUR Research Repository (Erasmus University Rotterdam)
Prognostic markers in pediatric leukemia and mechanisms of KRAS induced leukemogenesis
Staffas, A. (2013) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Neurofibromin and IL-4 as Regulators of T Cell Development, Function, and Homeostasis
Oliver, J. A. (2012) · Deep Blue (University of Michigan)
The Importance of Isoprenylation and Nf1 Deficiency in K-RAS-induced Cancer
Sjogren, A.-K. M. (2009) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
SnapShot:Mouse Models of Cancer
Zender, L., Zuber, J. A., & Lowe, S. W. (2007)
Möröy, T., Patel, C. V., Peeters, J. K., Löwenberg, B., Göttgens, B., Meyer, S. E., Grimes, H. L., van der Reijden, B. A., Jansen, J. H., Gaudreau, M., et al. (2013)
Sushma, C., Prasad, S., Devi, R., Murthy, S., Rao, T., & Naidu, C. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.8.3505
“Activated RAS stimulates RAF and mitogenactivated protein (MAP) kinase cascade to transmit growth signals to the nucleus (Chan et al., 2004; Stricker et al., 2010).”
Background[Reviews] Pathogenetic and clinical significance of genetic abnormalities in acute myeloid leukemia
Matsumura, I. (2010) · Institutional Repositories DataBase (IRDB)
Mediated by Ras Inhibition of Myeloid Differentiation Ral Is both Necessary and Sufficient for the
Darley, L., Omidvar, N., Pearn, L., Burnett, A. K., & Richárd (2014)
Markers for Diagnosis, Prognosis, and Therapy of Acute Myeloid Leukemia
Fuchs, O. (2013) · CRC Press eBooks · doi:10.1201/b16389-34
“Ras-signaling cascade contributes to the molecular pathogenesis of myeloproliferative disorders (Chan et al., 2004).”
BackgroundCytogenetics and molecular biology of chronic myeloid leukemia
Deininger, M. W. (2013) · CRC Press eBooks · doi:10.3109/9780203091616-6
Scalabrini, L. C. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.46.2017.tde-11042017-082202 · Cited by 1
Investigação das quinases Aurora A e Aurora B na tumorigenicidade mediada pelo oncogene KRAS
dos Santos, E. O. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2017.tde-21062017-103949 · Cited by 1
Miranda, V. S. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.46.2019.tde-01082019-085027
Oncogenic Forms of ABL Family Kinases
Ren, R. (2008) · Springer eBooks · doi:10.1007/978-0-387-68744-5_7
C ytogenetics and molecular biology of chronic myeloid leukemia
Rosée, P. G. L., & Deininger, M. W. (2008) · CRC Press eBooks · doi:10.3109/9780203091616-3
Case, M. C., Matheson, E. C., Minto, L., Hassan, R., Harrison, C. J., Bown, N. P., Bailey, S., Vormoor, J. H., Hall, A. G., & Irving, J. A. E. (2023) · doi:10.1158/0008-5472.c.6496418.v1
Dasgupta, B., Li, W., Perry, A., & Gutmann, D. H. (2023) · doi:10.1158/0008-5472.c.6492989
Oßwald, L., Hamarsheh, S., Uhl, F. M., Andrieux, G., Klein, C., Dierks, C., Duquesne, S., Braun, L. M., Schmitt-Graeff, A. H., Duyster, J., et al. (2023) · doi:10.1158/1541-7786.c.6544992.v1
Juvenile myelomonocytic leukaemia, a disease of the hematopoietic development ?
Strullu, M. (2020) · theses.fr (ABES) · doi:10.70675/4c43b75ez3802z430bzad4ez2e83408fd47a
Decroocq, J. (2019) · theses.fr (ABES) · doi:10.70675/6e933875z3629z4e49z9d73z698f1f919e4c
Cancerous time estimation for interpreting the evolution of lung adenocarcinoma
Han, Y., Chen, B., Bian, J., Kang, R., & Shang, X. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae520
“…by invasive adenocarcinoma after EGFR/TTF-1 amplification or the inactivation of TP53, while KRAS-or BRAF-mutated atypical adenomatous hyperplasia rarely progresses to adenocarcinoma in situ or invasive adenocarcinoma, but can do so after the inactivation of TP53 or other genomic events [38–40].”
Identificação de RNAs não codificadores longos regulados pelo oncogene KRAS em câncer de pâncreas
Corrêa, T. B. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2022.tde-09042025-160757
Wnt in Hematopoietic and Leukemic Stem Cells
Dao, K.-H. T., & Catriona, H. M. J. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-347-3_8
Genetically Engineered Mice Harboring RAS Mutations as Models of Human Cancer: in Medias RAS
Zaks, T. Z., Jacobetz, M. A., & Tuveson, D. A. (2006) · Springer eBooks · doi:10.1007/1-4020-4708-8_12
Self-citationBerg, J. L., Perfler, B., Hatzl, S., Mayer, M.-C., Wurm, S., Uhl, B., Reinisch, A., Klymiuk, I., Tierling, S., Pregartner, G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13535851
Preclinical Models of Head and Neck Squamous Cell Carcinoma
van den Brekel, M. W. M., Zuur, C. L., Malkoski, S. P., & Wang, X. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9464-6_12
“By placing a loxP-flanked stop codon upstream of an oncogene (e.g., Kras G12D ), this approach can also be used to “knock-in” tumor initiators [91, 92 ] or specific p53 mutations.”
Coppin, E. (2015) · theses.fr (ABES) · doi:10.70675/6957c36dz8f27z48f3z8280z053c2d8e66ec
Caye‐Eude, A. (2018) · theses.fr (ABES) · doi:10.70675/5970456azb8a7z44a5zad25zbcef6aab00b1
Modeling Chronic Myelomonocytic Leukemia with the Aim of Identifying Novel Therapeutic Targets
Alawieh, D. (2025) · theses.fr (ABES) · doi:10.70675/c7daf13fz397fz4894zbafezd95092b27414
EZH2 inactivation drives MAPK-dependent vulnerability to MEK inhibition in RAS-mutant CMMLPreprint
Gruden, E., Perfler, B., Kailasnathan, A., Chaida, P., Lind, K., Mayer, M.-C., Foßelteder, J., Kienzl, M., Dutta, S., Wurm, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.02.729524
Outcome heterogeneity in CALR ‐mutated myeloproliferative neoplasms
Mawalkar, R., Tsai, H., Paşca, S., Gondek, L. P., Halper‐Stromberg, E., Xian, R. R., Gocke, C. D., Rappazzo, K. C., Karantanos, T., Smith, B. D., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70859 · Cited by 1
Chan, I. T., & Gilliland, D. G. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-963-9_79
Self-citationMouse Models of RAS-Induced Tumors and Developmental Disorders
Guerra, C. E., & Barbacid, M. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1806-1_10
“In mice, activation of Ras signaling in the hematopoietic lineage, either by inactivating the Nf1 tumor suppressor or by expressing an endogenous K-Ras allele in cells of hematologic lineage in the K-Ras;Mx1-Cre strain, is sufficient to induce a fatal myeloproliferative disorder (MPD) similar to that observed in human…”
Result
Metadata
- Authors
- Chan, I. T., Kutok, J. L., Williams, I. R., Cohen, S., Kelly, L., Shigematsu, H., Johnson, L., Akashi, K., Tuveson, D. A., Jacks, T., & Gilliland, D. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Emory University (US)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Exelixis (United States) (US)
- Abramson Cancer Center (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Gilliland, D. Gary
- Venue
- Journal of Clinical Investigation
- Published
- 2004-02-15
- Volume
- 113
- Issue
- 4
- Pages
- 528-538
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC338267
- OpenAlex
- W2147839086
- Cited by
- 270
- References
- 73
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 9 · 2020: 3 · 2019: 8 · 2018: 8 · 2017: 12 · 2016: 9 · 2015: 10 · 2014: 13 · 2013: 16 · 2012: 12
- FWCI
- 14.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Leukemia and Lymphoma Society
- National Institutes of Health (CA66996)
- National Cancer Institute (#CA66996, P01CA066996)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK51564)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Keywords
- oncogenic KRAS, endogenous promoter, conditional alleles, Cre-mediated recombination, myeloproliferative neoplasms, acute myeloid leukemia, hematopoietic system, myeloid hyperplasia, extramedullary hematopoiesis, cooperating mutations, RAS inhibitors, gene dosage
- MeSH terms
- Adenoma, Alleles, Animals, Bone Marrow Cells, Cells, Cultured, Hematopoietic Stem Cells, Humans, Mice, Inbred Strains, Mice, Transgenic, Myeloproliferative Disorders, Neoplasms, Papilloma, Phenotype, Promoter Regions, Genetic, Genes, ras, Leukemia, Myeloid, Acute, Gene Expression Regulation, Neoplastic, Bone Marrow Transplantation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.